VivoSeq
Other

Magnesium Deficiency

2

Pipeline Programs

1

Active Trials

1

Companies Involved

Magnesium Deficiency is an early-stage landscape with 2 programs across 1 company. The most active players are Fresenius Kabi Oncology Ltd.. 2 therapies are approved.

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs

Trial Status

1

clinical trials

Recruiting1 · 100%

Trial Activity

Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards
Recruiting··Phase 4·NCT03088852·330 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)